New England News Collaborative

SaverOne Continues its Successful Execution on its Strategy with Strong Revenue Growth of 165% for its Full Year 2022 Results

Retrieved on: 
Thursday, March 30, 2023

PETAH TIKVAH, Israel, March 30, 2023 /PRNewswire/ -- SaverOne 2014 Ltd. (Nasdaq: SVRE) (TASE: SVRE), a company developing and deploying transportation safety and advanced driver-assistance systems (ADAS) technologies and solutions, today presented its results for the year ended December 31, 2022 and presented some of its recent business updates.

Key Points: 
  • Commented Mr. Ori Gilboa, CEO of SaverOne, "We are very pleased with both our strategic and strong commercial progress in 2022.
  • "We see our strong success in recent months as only the early indications of the significant long-term potential still ahead of us.
  • We continue to become increasingly optimistic about our prospects for SaverOne and I look forward to realizing that potential," concluded Mr. Gilboa.
  • Following a successful pilot Moviley Dror broadens SaverOne program: Moviley Dror decided to install the SaverOne protection system across its full fleet of 150 vehicles.

Avicanna Reports Q3 2022 Financial Statement

Retrieved on: 
Monday, November 14, 2022

TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

Key Points: 
  • TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
  • ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS
    TORONTO, November 14, 2022 (GLOBE NEWSWIRE) Avicanna Inc. (Avicanna or the Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce the filing of its interim financial statements for the three-month period ending September 30, 2022 (Q3 2022).
  • The process of technical transfer and product re-registrations however, resulted in short term stocking gaps and lower than expected revenues in late Q2 and Q3.
  • Ventures, Inc. for Avicanna to utilize its existing scientific platform and drug delivery systems to develop and commercialize Psilly branded functional fungi-based products.

SaverOne Presents Results & Business Update for the First Half of 2022

Retrieved on: 
Thursday, September 8, 2022

PETAH TIKVAH, Israel , Sept. 8, 2022 /PRNewswire/ -- SaverOne 2014 Ltd. (Nasdaq: SVRE, TASE: SVRE), a technology company engaged in transportation safety solutions, today presented its results for the first half of 2022 and recent business updates. 

Key Points: 
  • PETAH TIKVAH, Israel, Sept. 8, 2022 /PRNewswire/ -- SaverOne 2014 Ltd. (Nasdaq: SVRE, TASE: SVRE), a technology company engaged in transportation safety solutions, today presented its results for the first half of 2022 and recent business updates.
  • Commented Ori Gilboa, CEO of SaverOne, "The past few months have been exceptionally active for SaverOne.
  • As of June 30, 2022, SaverOne had NIS 41 million (approximately $11.7 million) in cash and cash equivalents and short-term bank deposits.
  • Many factors could cause SaverOne's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements.

Mersana Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results

Retrieved on: 
Monday, May 9, 2022

Mersana expects to disclose interim data from this cohort in Q4 2022, with a primary focus on safety and tolerability.

Key Points: 
  • Mersana expects to disclose interim data from this cohort in Q4 2022, with a primary focus on safety and tolerability.
  • General and administrative (G&A) expenses for the first quarter of 2022 were $12.8 million, compared to $7.2 million during the same period in 2021.
  • ET to discuss its financial results for the first quarter of 2022 and business updates.
  • Mersana Therapeutics was recently named among the 2021 Top Places to Work in Massachusetts by The Boston Globe.